Health-related quality of life and symptom-specific functional impairment among patients treated with parenterally administered complement inhibitors for paroxysmal nocturnal hemoglobinuria
2024

Quality of Life and Impairment in Patients with Paroxysmal Nocturnal Hemoglobinuria

Sample size: 61 publication 10 minutes Evidence: moderate

Author Information

Author(s): Dingli David, Rizio Avery A., Broderick Lynne, LaGasse Kaitlin, Rucker Sloan, Carty Michelle K., Burton Elise, Gordon Shaquilla, Yen Glorian P., Paulose Jincy, Geevarghese Anumaxine, Lee Soyon

Primary Institution: Mayo Clinic, Rochester, MN USA

Hypothesis

Patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with complement inhibitors experience worse health-related quality of life (HRQoL) and functional impairment compared to the general population.

Conclusion

Patients with PNH treated with complement inhibitors reported significantly worse HRQoL and greater functional impairment than age- and sex-matched adults from the general population.

Supporting Evidence

  • Patients treated with PACIs for PNH had significantly worse HRQoL and greater functional impairment for all measured domains.
  • Statistically significant associations were observed between fatigue severity and HRQoL/functional impairment for all outcomes except sleep disturbance.
  • Qualitative interviews revealed that fatigue significantly impacts physical, social, and cognitive functioning.

Takeaway

People with a rare blood condition called PNH still feel very tired and have trouble doing everyday things, even after getting treatment.

Methodology

The study used an online survey and qualitative interviews to assess HRQoL and functional impairment in patients with PNH compared to a matched general population sample.

Potential Biases

Potential selection bias due to recruitment methods and participant characteristics.

Limitations

The study's cross-sectional design limits causal inferences, and selection bias may affect sample representativeness.

Participant Demographics

Participants included adults with PNH treated with complement inhibitors, primarily Caucasian, with a mean age of approximately 47 years.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s00277-024-06088-x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication